KZIA - CONSENSUS CO - Kazia Therapeutics

This chart of Kazia Therapeutics (KZIA) share prices illustrates the asset's dynamics, with its current value standing at 31.21. Kazia Therapeutics (KZIA) utilizes automated genome analysis and cell imaging for drug discovery, focusing on therapies for glioblastoma and rare neoplasms. Financial success depends on the development of inhibitors capable of crossing the blood-brain barrier, although the business is currently facing a liquidity shortage due to costly clinical trials.

The consensus target price from analyst coverage reflects the status of Kazia Therapeutics (KZIA) as a high-tech player in oncology, whose patents for Paxalisib create significant barriers to entry for competitors. This indicator aggregates average expert expectations for fair value, filtering out market noise and allowing investors to compare the business's actual potential with the FDA's stringent requirements for clinical phases.